A randomized controlled trial evaluates if selective early treatment of patent ductus arteriosus reduces death or bronchopulmonary dysplasia at 36 weeks in extreme preterm babies.
Study assesses whether early targeted treatment of patent ductus arteriosus improves outcomes in extreme preterm babies
A randomized controlled trial evaluates if selective early treatment of patent ductus arteriosus reduces death or bronchopulmonary dysplasia at 36 weeks in extreme preterm babies.